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All patients at the Medical College of Wisconsin Afﬁliated Hospitals with a new diagnosis of bullous pemphigoid
(BP) between May 1, 1997 and September 1, 2002 were included in this study. The age at onset, date of death or date
of last follow-up visit, mode of treatment, co-morbidities, and initial and follow-up hospitalizations were noted.
Thirty-eight new patients were identiﬁed and complete follow-up data were obtained on 37 of the patients. Patients
were followed a minimum of 1 y or until the time of death. The mean duration of follow-up was 20 mo. Kaplan–Meier
analysis of our population indicated a 1-y survival probability of 88.96% (standard error 5.21%), with a 95%
conﬁdence interval (75.6%, 94.2%). This survival rate was considerably higher than that recently reported in several
studies from Europe (29%–41% ﬁrst year mortality). Although the age at onset and co-morbidities of our patients
were similar to those in the European studies, the rate of hospitalization of our patients was much lower than that of
patients from Europe (1.5 d per patient vs 11–25 d per patient). This study suggests that differences in practice
patterns may be an important factor in the reduced mortality rate in US BP patients compared with Europe.
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Bullous pemphigoid (BP) is the most common of the
autoimmune blistering diseases with an estimated inci-
dence of 10 cases per million population (Korman, 1998).
Since it is a disease primarily of the elderly, with an average
onset in the eighth decade, concern has been raised that as
the population is aging the incidence may also be rising
(Jung et al, 1999). BP is characterized by the development
of tense blisters of the skin, most commonly on an
erythematous base. The autoimmune basis of BP was
suggested by Jordon et al (1967) with their identification of
the deposition of IgG and complement components in the
skin of BP patients. Two hemidesmosomal proteins, BP180
and BP230, have been identified as the targets of the
autoantibodies in BP (Stanley et al, 1981; Labib et al, 1986).
A passive-transfer mouse model of BP strongly suggests
that antibodies directed against the BP180 protein are of
primary pathogenic importance in the development of the
disease (Liu et al, 1993).
Large, current studies examining the mortality rate of BP
patients in the US are lacking. Recent studies from Europe
have shown a significant mortality in the first year following
the diagnosis of BP ranging from 29% to 41% (Bernard et al,
1995, 1997; Roujeau et al, 1998; Joly et al, 2002; Rzany et al,
2002). These studies suggested that predictive factors of
death in the first year were: age at onset, low serum albumin
level, and pre-existing cardiovascular disease. In contrast,
Venning and Wojnarowska (1992) reported a 1-y mortality of
19% and could not identify specific risk factors. One study
from the US indicated a 6% mortality at 2 y (Ahmed et al,
1977). A more recent therapeutic study had a 5% death rate
but two patients were lost to follow-up (if these were
assumed dead, the rate would rise to 15%) (Fivenson et al,
1994). No similar recent studies have looked specifically at
the mortality from this disease in the US. In this study, we
retrospectively studied the mortality of all BP patients newly
diagnosed at the Medical College of Wisconsin Affiliated
Hospitals from 1998 until 2002.
Results
Thirty-eight patients with BP were identified. One of the
patients moved out of state prior to completing 1 y of
follow-up and was not included in the study. Of the 37
remaining patients, follow-up was obtained on 100% of the
patients. The mean duration of follow-up for these patients
was 20 mo.
The average age of our patients at the time of diagnosis
was 77 y with a range from 41 to 98 y. Nineteen patients
were female and 18 were male. There was no significant
difference between the male and female patients with
regard to age (M¼74.7 y, F¼ 79.6 y) or co-morbidities. Two
patients were African–American and the rest were Cauca-
sian. Cardiovascular disease was the most common pre-
existing condition in our patients, identified in 59% of the
patients. Diabetes was present in 15% prior to corticoster-
oid use, and neuropsychiatric disease in 19%. Chronic renal
disease was present in 8%. In addition, a large number of
patients had other autoimmune diseases, including multiple
sclerosis (n¼ 2), thyroid disease (n¼2), and one each with
pemphigus vulgaris (PV), pemphigus foliaceus (PF), inflam-
matory bowel disease, rheumatoid arthritis, and polymyal-
gia rheumatica. The patients with pemphigus had been
diagnosed 9 and 25 y prior to the onset of BP and neither
patient had evidence of pemphigus at the time of the
diagnosis of BP. Autoantibodies to desmoglein 1 and 3
could not be detected in either patients’ sera by ELISA. TheAbbreviation: BP, bullous pemphigoid
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medical record of the PV patient indicated confirmation of
the diagnosis by histology, direct, and indirect IF; however,
archived tissue was only available for histology. Review of
the histology showed suprabasilar acantholysis consistent
with PV. Stored serum was available in the patient with PF,
and ELISA determination from this patient at the time of the
diagnosis of PF confirmed the presence of desmoglein 1
autoantibodies, but not desmoglein 3 or BP180 autoanti-
bodies. Interestingly, both patients who had previously been
diagnosed with a form of pemphigus died during the study,
one 5 mo following the diagnosis of BP, the other after 2 y.
Twenty-eight patients (76%) were treated initially with
systemic prednisone. The range for the highest dosage of
prednisone was 10–80 mg per d. Seven patients were
treated with a maximum dose of approximately 1 mg per kg
per d and 17 patients with less than 0.5 mg per kg per d.
Four patients’ highest maximum dose was approximately
0.75 mg per kg per d. Of these patients, 22 also received a
second immunosuppressive agent including mycophenolic
acid (n¼5), cyclophosphamide (n¼ 1), azathioprine (n¼ 11),
and dapsone (n¼7). One patient received intravenous
immunoglobulin as an adjunct therapy. Two patients were
treated with tetracycline and nicotinamide without steroids,
one patient was treated with dapsone alone, and six
patients were treated with topical steroids only.
Three patients were hospitalized when the diagnosis of
BP was initially made. The average duration of hospitaliza-
tion was 4.7 d. One of these patients was hospitalized three
subsequent times to receive intravenous immunoglobulin
therapy for his BP (Ahmed, 2001); the average stay for these
additional hospitalizations was 2 d. Four additional patients
were hospitalized during the study for problems other than
BP. One each had bowel obstruction, pneumonia, compli-
cations of hemophilia, and exacerbation of asthma requiring
hospitalization. The average duration of hospitalization for
these four patients was 9 d. When examined over the entire
patient base, the average initial hospitalization in our
patients was 0.4 hospital days per patient. The average
hospitalization throughout the course of our study for any
reason was 1 hospital day per patient.
Four patients died during the first year following the
diagnosis of BP (10.8%). All four of the patients who died
within the first year following the diagnosis of BP were male
and the mean age of the patients who died was 73 y. The
characteristics of the patients who died within the first year
following the diagnosis of BP are listed in Table I. Two
additional patients died more than 1 y after diagnosis, one
after 16 mo, and another after 24 mo of follow-up. There
was one male and one female in the group that died after
more than 12 mo, with a mean age of 86 y.
The results of the Kaplan–Meier analysis are shown in Fig
1. The 1-y survival probability was 88.96% (standard error
5.21%), with a 95% confidence interval of (75.6%, 94.2%).
Discussion
The first-year mortality in the patients in our study was
10.8% and overall six patients died during the study. These
deaths could be due to natural causes, as a result of BP,
or related to the therapy they received. Examination of the
causes of death in our patients does not provide strong
evidence of a relationship to their disease or therapy. Two
patients died in their nursing homes at ages 96 and 98 y,
Table I. Characteristics of the patients who died during the study
Cause of death Age/sex
Time from diagnosis
to death (mo) Co-morbidity Treatment prior to death
Gastrointestinal hemorrhage 53/M 6 Diabetes P 50 mg per 2.5 mg (alternate days)
Hyperlipidemia DAP 100 mg per d
Hypertension
Alcohol abuse
Cerebrovascular accident 81/M 3 Multiple cerebrovascular accidents P 60 mg QOD
TCN 1500 mg per d
NIC 1500 mg per d
? 98/M 1 Dementia Topical steroids
Myocardial infarction 60/M 5 Dementia No treatment
Cardiovascular disease
Pemphigus vulgaris (inactive)
? 96/F 16 Dementia P 10 mg QOD
Acute and chronic 79/M 24 Pemphigus foliaceus (inactive) P 2.5 mg QOD
Renal failure Psoriasis
Chronic renal failure
P, prednisone; AZA, azathioprine; DAP, dapsone; TCN, tetracycline; NIC, nicotinamide.
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respectively. Both patients suffered from dementia and an
autopsy was not performed on either of these patients as
these deaths were deemed to be of natural causes. One
patient who died of a myocardial infarction had pre-existing
cardiovascular disease, mild BP, and refused treatment. The
patient who died of a cerebrovascular accident had had
several previous strokes and was aphasic and non-
ambulatory at the time he developed BP. Although he was
on prednisone at the time he died, he was not hypertensive
and a relationship between prednisone and stroke has not
been identified. One patient had long-standing chronic renal
failure, predating the onset of this BP by many years, and
died of an acute exacerbation. The use of systemic steroids
could be related to gastrointestinal (GI) hemorrhage, the
cause of death in the final patient. This patient, however,
also had multiple other medical problems including alcohol
abuse that could also contribute to the risk for GI bleeding.
The mean age of death in these patients, 77.2 y, is almost
identical to the current life expectancy in the US (77.2 y)
(Arias and Smith, 2003).
Our study showed a significantly lower mortality in the
first year following the diagnosis of BP (10.8%) than that
previously reported in studies from Europe (Bernard et al,
1995, 1997; Roujeau et al, 1998; Joly et al, 2002; Rzany
et al, 2002). These studies from France and Germany
indicate a first-year mortality of 29%–41%. Even patients
from France who were treated without systemic agents had
a 24% mortality rate in the first year (Joly et al, 2002).
The recent study by Rzany et al (2002) suggests that
this increased mortality in the first year may be in part
attributable to higher doses of corticosteroids and in-
creased age. Korman (1998), however, argues that because
earlier studies reporting lower mortalities had comparable
ages of disease onset, it is unlikely that a more advanced
age accounted for the higher mortality in the French study.
Korman states that a selection bias may have accounted for
the higher mortality, given that the patients were seen at
large referral centers. He also suggests that significant
variations in survival may exist due to ethnicity, because
the mortalities in several other French studies were also
comparably high. Our patients were also from a tertiary care
referral center and the co-morbidities in our patients were
similar to those reported from France, making selection bias
less likely as an explanation for the difference seen in
survival. We cannot rule out differences in ethnicity or other
cultural factors in the differences in survival.
The patients reported in all of these studies were
recruited from academic medical centers, so are likely to
represent a similar population with regard to severity and
co-morbidities. But one striking difference in the manage-
ment pattern of patients with BP is the rate of hospitalization
in the European patients compared with our center. The
standard of care in Europe is that almost all patients are
initially hospitalized when the diagnosis of BP is made. The
most careful assessment of hospitalization was reported
by Joly et al (2002). The initial hospitalization in their
Figure 1
Kaplan–Meier curve of survival in bullous pempigoid. Four deaths occurred in the first year of follow-up and two additional at 16 and 24 mo. The
1-y survival probability of 88.96% (standard error 5.21%), indicated by the solid line. The confidence intervals (75.6%, 94.2% at 12 mo) are indicated
by the dotted lines.
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study averaged between 9 and 17 hospital days per patient
depending on the extent of the disease and the mode of
treatment. In contrast, patients are rarely hospitalized in our
center for the initial treatment of BP. Only three of 37 were
initially hospitalized with an average duration of 4.7 d or 0.4
hospital days per patient. During the course of follow-up,
one of these patients was hospitalized three additional
times for BP, in order to receive intravenous immunoglobulin
therapy. The average duration of the hospitalization for
these additional stays was 2 d. The cumulative hospitaliza-
tion of our BP patients for any reason throughout the study
was 1.0 hospital days per patient. In comparison, Joly’s
patients were hospitalized from 11 to 25 hospital days per
patient in a study of similar duration (Joly et al, 2002).
The increased mortality in BP in the first year after
diagnosis was reported by Roujeau et al (1998) to be due to
sepsis (23 of 46 cases), and to a lesser extent, cardiovas-
cular diseases (11 of 46). The cause of death was not known
in 20 cases, and of the 23 who died of sepsis, 11 had
concomitant pneumonitis. Joly et al (2002) reported similar
rates of sepsis. Twenty-seven of 71 patients in whom a
cause of death could be confirmed were attributed to
sepsis. Twenty of those 27 had concomitant pneumonia.
Statistics on the incidence of sepsis in this country and
abroad are unfortunately incomplete, largely due to differ-
ences in defining the condition and reporting parameters.
Sepsis is a contributing factor in4100,000 deaths per y in
the United States. Approximately two-thirds of cases occur
in patients hospitalized for other illnesses. Advanced age,
chronic diseases, immunosuppression, indwelling catheters,
and mechanical ventilation are associated with increased
incidence of sepsis (Munford, 2001). A recent analysis by
Angus et al (2001) estimated an incidence of 3.0 cases per
1000 population and 2.26 cases per 100 hospital discharges
in the United States. Both incidence and mortality due to
sepsis increased markedly with age in this report. Another
analysis from eight academic centers in the US reported an
incidence of 2.0 cases per 100 admissions (Sands et al,
1997). A multicenter study from 24 hospitals in France found
an incidence of bacteremia and severe sepsis of 9.8 and 2.6,
respectively, per 1000 adult admissions (Brun-Buisson et al,
1996). It was found that an independent risk factor for severe
sepsis during bacteremia included age. A study from Israel
found that hospital-acquired sepsis was associated with a
higher mortality. In this study, 39% of cases of sepsis were
hospital-acquired (Sonnenblick et al, 1990).
As evidenced by these reports, sepsis is largely a
syndrome experienced by hospitalized patients as a
complication of other conditions. Furthermore, incidence
of and mortality due to sepsis apparently increases with
age. The discrepancy between the reported mortality rates
of BP patients across various studies could be due to rates
of hospitalization (and therefore incidence of sepsis) and not
directly due to age. This might explain the unusually high
mortality of BP patients in Western Europe where initial
hospitalization for diagnosis of BP is the norm.
Although the differences in hospitalization are intriguing
we cannot rule out other geographic or ethnic differences
that could account for the higher mortality in BP patients
from Europe. Further careful studies of treatment modalities
(including a direct comparison of ambulatory and hospita-
lized patients) and outcomes in these patients are needed.
Our study also underscores the wide variability in the
mortality of BP that may exist in difference sites. Normative
data within one’s own center are needed when studying
these disorders until there is a better understanding of the
factors that may influence survival.
Materials and Methods
Patient cohort All patients newly diagnosed with BP at the
Medical College of Wisconsin Affiliated Hospitals between May
1, 1997 and September 1, 2002 were included in the study. The
study was approved by the Human Research Review Committee of
the Medical College of Wisconsin Affiliated Hospitals (#230-01)
and was performed in adherence to the Declaration of Helsinki
Guidelines. All patients had confirmation of the diagnosis of BP by
histology and immunofluorescent testing. All patients demon-
strated autoantibodies against BP180 and/or BP230, which was
previously performed in these patients as part of another research
study (Dimson et al, 2002). The age at onset, method of treatment
(including the highest dose of prednisone used), pre-existing co-
morbidities, days of initial and/or subsequent hospitalizations, and
the reasons for hospitalization were recorded. The last follow-up or
date of death was also identified. If a patient died, the medications
they were receiving for BP at the time of death were noted.
Patients were followed for a minimum of 1 y or until the time of
death.
Statistical analysis The Kaplan–Meier method was used to
estimate the survival probability and the survival standard error.
The log-transform method was used to estimate confidence
intervals for the survival probability. This analysis was performed
with SAS statistical software (The SAS Institute, Cary, North
Carolina).
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